Creating value through cutting-edge science and an unwavering commitment to patients
At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA and other CNS-related disorders, totaling over 40 therapies in various stages of development. Our programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.
Our work is purposeful, audacious, urgent. Our commitment to do well by patients is unyielding as we build our position as the world's leader in precision genetic medicine.
|9/27/21||Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA|
|9/14/21||Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress|
|9/7/21||Sarepta Therapeutics to Present at Upcoming Investor Conferences|
Data Provided by Refinitiv. Minimum 15 minutes delayed.
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in releases or in our posted events and presentations are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings. Sarepta does not undertake any obligation to update forward-looking statements after the date of such releases expect to the extent required under applicable federal and state securities laws.
This website contains links to websites maintained by other companies. Sarepta is providing these links to readers only as a convenience. The inclusion of any link does not imply that Sarepta endorses any third-party website or third-party company or product. Sarepta does not have any control over the content of such third-party websites and assumes no responsibility whatsoever for the functionality of such websites or for the accuracy of any information presented at such other websites.